CA2222133A1 - Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen - Google Patents

Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen

Info

Publication number
CA2222133A1
CA2222133A1 CA002222133A CA2222133A CA2222133A1 CA 2222133 A1 CA2222133 A1 CA 2222133A1 CA 002222133 A CA002222133 A CA 002222133A CA 2222133 A CA2222133 A CA 2222133A CA 2222133 A1 CA2222133 A1 CA 2222133A1
Authority
CA
Canada
Prior art keywords
estrogen
combination
transdermal patch
administering
deacetyl norgestimate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002222133A
Other languages
French (fr)
Other versions
CA2222133C (en
Inventor
Janan Jona
Jay Audett
Noel Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Cygnus, Inc.
Janan Jona
Jay Audett
Noel Singh
Cygnus Therapeutic Systems
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27044166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2222133(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cygnus, Inc., Janan Jona, Jay Audett, Noel Singh, Cygnus Therapeutic Systems, Ortho-Mcneil Pharmaceutical, Inc. filed Critical Cygnus, Inc.
Publication of CA2222133A1 publication Critical patent/CA2222133A1/en
Application granted granted Critical
Publication of CA2222133C publication Critical patent/CA2222133C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Abstract

Compositions and methods for preventing ovulation in a woman are provided, as well as compositions and methods for female hormone replacement therapy. The compositions can be administered by the use of a transdermal patch. The patch will administer 17-deacetyl norgestimate alone or in combination with an estrogen such as ethinyl estradiol to women.
CA002222133A 1995-06-07 1996-06-06 Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen Expired - Lifetime CA2222133C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47353195A 1995-06-07 1995-06-07
US08/473,531 1995-06-07
US51726395A 1995-08-21 1995-08-21
US08/517,263 1995-08-21
PCT/US1996/009396 WO1996040355A1 (en) 1995-06-07 1996-06-06 Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen

Publications (2)

Publication Number Publication Date
CA2222133A1 true CA2222133A1 (en) 1996-12-19
CA2222133C CA2222133C (en) 2002-12-24

Family

ID=27044166

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002222133A Expired - Lifetime CA2222133C (en) 1995-06-07 1996-06-06 Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen

Country Status (22)

Country Link
US (3) US5876746A (en)
EP (1) EP0836506B2 (en)
JP (2) JP3534775B2 (en)
KR (1) KR100301226B1 (en)
CN (1) CN1188189C (en)
AT (1) ATE229828T1 (en)
AU (1) AU703593B2 (en)
CA (1) CA2222133C (en)
CZ (1) CZ292151B6 (en)
DE (1) DE69625483T3 (en)
DK (1) DK0836506T4 (en)
ES (1) ES2190472T5 (en)
HU (1) HU228434B1 (en)
IL (1) IL122432A (en)
MX (1) MX9709666A (en)
NO (1) NO316308B1 (en)
NZ (1) NZ311304A (en)
PL (1) PL181582B1 (en)
PT (1) PT836506E (en)
RU (1) RU2177311C2 (en)
UA (1) UA48973C2 (en)
WO (1) WO1996040355A1 (en)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE19549264A1 (en) * 1995-12-23 1997-06-26 Schering Ag Contraception procedure and kit
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US5939477A (en) * 1998-02-02 1999-08-17 Dow Corning Corporation Silicone pressure sensitive adhesive composition containing functionalized polyisobutylene
DE19814084B4 (en) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
DE19834007C1 (en) * 1998-07-29 2000-02-24 Lohmann Therapie Syst Lts Estradiol-containing patch for the transdermal application of hormones and its use
ES2379471T5 (en) † 1999-02-08 2015-05-26 Intarcia Therapeutics, Inc Non-aqueous single phase biocompatible viscous vehicles and procedures for their preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6417227B1 (en) 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
WO2001000116A1 (en) * 1999-06-25 2001-01-04 Schmidt Jonalee M Hairpiece and method for attaching same
DE19943317C1 (en) * 1999-09-10 2001-03-15 Lohmann Therapie Syst Lts Plastic films, in particular for use in a dermal or transdermal therapeutic system and process for their manufacture
JP4841781B2 (en) * 1999-11-24 2011-12-21 アジル・セラピューティクス・インコーポレイテッド Improved transdermal contraceptive delivery system and method
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
US7384650B2 (en) 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US7223418B2 (en) * 2000-03-07 2007-05-29 Tiejin Limited Stretchable patch
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US7235397B1 (en) 2000-04-14 2007-06-26 Gensys, Inc. Methods and compositions for culturing spirochete and treating spirochetal diseases
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
DE10041478A1 (en) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040039356A1 (en) * 2000-10-16 2004-02-26 Masayoshi Maki Compositions for external preparations
US20020106402A1 (en) * 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
US8840918B2 (en) * 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8728445B2 (en) 2001-05-01 2014-05-20 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences Hydrogel Compositions
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
DE60239528D1 (en) * 2001-05-01 2011-05-05 Corium International Redwood City TWO-PHASE, WATER-ABSORBING BIOADHESIVE COMPOSITION
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
WO2003024450A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
WO2003063927A2 (en) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
WO2003053221A2 (en) * 2001-12-19 2003-07-03 Eisai Co. Ltd Methods using proton pump inhibitors
CA2478336A1 (en) * 2002-03-11 2003-09-25 Janssen Pharmaceutica N.V. Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
JP2005519962A (en) * 2002-03-11 2005-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Continuous progestogen contraceptive regimen that inhibits sulfatase
JP2005519964A (en) * 2002-03-11 2005-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Sulfatase-inhibiting progestogen-only contraceptive regimen
US20030219471A1 (en) * 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
ATE336252T1 (en) * 2002-03-11 2006-09-15 Janssen Pharmaceutica Nv CONTINUOUS SULFATASE-INHIBITING PROGESTOGEN CONTAINING HORMONE SUBSTITUTION THERAPY
US7223386B2 (en) * 2002-03-11 2007-05-29 Dow Corning Corporation Preparations for topical skin use and treatment
US20040142914A1 (en) * 2002-03-11 2004-07-22 Friedman Andrew Joseph Extended transdermal contraceptive regimens
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
AU2003241464A1 (en) * 2002-05-17 2003-12-02 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US20050245492A1 (en) 2004-04-28 2005-11-03 Lephart Edwin D Use of equol for treating skin diseases
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
DE10234673B4 (en) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
SI1426049T1 (en) * 2002-12-02 2005-08-31 Sanol Arznei Schwarz Gmbh Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE10261696A1 (en) 2002-12-30 2004-07-15 Schwarz Pharma Ag Device for the transdermal administration of rotigotine base
ME00147B (en) 2003-02-21 2010-10-10 Schering Ag Uv stable transdermal therapeutic plaster
ATE487492T1 (en) * 2003-02-27 2010-11-15 Eisai R&D Man Co Ltd PHARMACEUTICAL COMPOSITION FOR TREATING DRUG DEPENDENCE
HUP0301981A2 (en) * 2003-06-30 2005-04-28 Richter Gedeon Vegyészeti Gyár Rt. Pure d-(17alpha)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3e-and-3z-oxime isomers, process for the synthesis of the mixture of isomers and the pure isomers
HUP0301982A2 (en) * 2003-06-30 2005-04-28 Richter Gedeon Vegyészeti Gyár Rt. Process for the preparation of high purity d-(17alpha)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime
US7816546B2 (en) 2003-06-30 2010-10-19 Richter Gedeon Vegyeszeti Gyar Rt. Process for the synthesis of high purity d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime
JP2007502831A (en) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
AU2004270161A1 (en) * 2003-08-28 2005-03-17 Nicox S.A. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
JP4965263B2 (en) * 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト Transdermal delivery of hormones without the need for penetration enhancers
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
CA2554716A1 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
AU2005210637B2 (en) 2004-01-30 2010-09-16 A.V. Topchiev Institute Of Petrochemical Synthesis Rapidly dissolving film for delivery of an active agent
US20050191338A1 (en) * 2004-01-30 2005-09-01 Lifeng Kang Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof
DE102004028284A1 (en) * 2004-06-11 2006-01-05 Hexal Ag Matrix-controlled transdermal therapeutic system based on a hotmelt adhesive for the application of norelgestromin
KR20070048229A (en) * 2004-08-05 2007-05-08 코리움 인터네셔널, 인크. Adhesive composition
JP4824963B2 (en) * 2004-08-12 2011-11-30 日東電工株式会社 Patch and patch preparation
JP4745747B2 (en) * 2004-08-12 2011-08-10 日東電工株式会社 Fentanyl-containing patch preparation
US20060121102A1 (en) * 2004-09-27 2006-06-08 Chia-Ming Chiang Transdermal systems for the delivery of estrogens and progestins
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
NZ582975A (en) 2004-10-21 2011-07-29 Durect Corp Transdermal delivery systems delivering sufentanil
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
JP2008528507A (en) * 2005-01-21 2008-07-31 ニトロメッド インコーポレーティッド Cardiovascular compounds containing heterocyclic nitric oxide donor groups, compositions and methods of use
CN1318032C (en) * 2005-01-24 2007-05-30 浙江大学 Ethinyl estradiol gas permeable absorbing paste
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20090042819A1 (en) * 2005-02-16 2009-02-12 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
AU2006218766A1 (en) * 2005-02-28 2006-09-08 Nicox S.A. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
JPWO2006093066A1 (en) * 2005-02-28 2008-08-07 久光製薬株式会社 Adhesive substrate and medical patch preparation containing the adhesive substrate
JP2008533031A (en) * 2005-03-09 2008-08-21 ニトロメッド インコーポレーティッド Organic nitric oxide enhancing salts, compositions and methods of use of angiotensin II antagonists
US20090131480A1 (en) 2005-04-04 2009-05-21 Eisai Co., Ltd. Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
US20060253963A1 (en) * 2005-05-10 2006-11-16 Limbaugh John M Body keep
US20090048219A1 (en) * 2005-05-23 2009-02-19 Nitromed Inc. Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
US7874489B2 (en) * 2005-06-20 2011-01-25 Authentiform Technologies, Llc Product authentication
US8458475B2 (en) * 2005-06-20 2013-06-04 Authentiform Technologies, L.L.C. Systems and methods for product authentication
US8247018B2 (en) * 2005-06-20 2012-08-21 Authentiform Technologies, Llc Methods for quality control
WO2007011763A2 (en) * 2005-07-15 2007-01-25 3M Innovative Properties Company Adhesive sheet and methods of use thereof
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
US20070098772A1 (en) * 2005-09-23 2007-05-03 Westcott Tyler D Transdermal norelgestromin delivery system
EP1945030A4 (en) * 2005-10-04 2009-10-21 Nitromed Inc The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
AU2006299383A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
AU2006299833B2 (en) 2005-10-12 2012-04-12 Besins Healthcare Luxembourg Sarl Improved testosterone gel and method of use
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc Furoxan compounds, compositions and methods of use
EP1968584A2 (en) * 2005-12-20 2008-09-17 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
EP2010169A4 (en) * 2006-04-10 2010-09-08 Nitromed Inc Assessment of heart failure risk using genetic assessment of g-protein beta-3 subunit polymorphism
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
EP2056814B1 (en) 2006-08-16 2014-05-21 Amderma Pharmaceuticals, Llc 2,5-dihydroxybenzene compounds for the treatment of psoriasis
DE102006050558B4 (en) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing norelgestromin for contraception and hormone replacement
ES2388355T3 (en) 2006-11-03 2012-10-11 Durect Corporation Transdemic delivery systems comprising bupivacaine
WO2008067409A2 (en) * 2006-11-28 2008-06-05 Polyplus Battery Company Protected lithium electrodes for electro-transport drug delivery
BRPI0719307A2 (en) * 2006-12-01 2014-02-04 Nitto Denko Corp METHOD FOR THE DELETION OF DECOLORATION OVER TIME OF PREPARATION STICKING CONTAINING DONEPEZIL.
EP2098232B1 (en) * 2006-12-01 2013-06-05 Nitto Denko Corporation Percutaneous absorption preparation
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
CN101715340A (en) 2007-04-23 2010-05-26 精达制药公司 The mixed suspension preparation of insulinotropic peptide and application thereof
JP2010524844A (en) * 2007-04-26 2010-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Cinnamide compounds for dementia
DE102007020799A1 (en) 2007-05-03 2008-11-06 Novosis Ag Transdermal therapeutic system with remifentanil
US20090005824A1 (en) * 2007-06-29 2009-01-01 Polyplus Battery Company Electrotransport devices, methods and drug electrode assemblies
JP5192296B2 (en) * 2007-07-05 2013-05-08 日東電工株式会社 Patches and patch preparations
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
US20090069740A1 (en) * 2007-09-07 2009-03-12 Polyplus Battery Company Protected donor electrodes for electro-transport drug delivery
JP5209433B2 (en) * 2007-10-19 2013-06-12 日東電工株式会社 Patch preparation
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CA2725484A1 (en) * 2008-05-30 2009-12-03 Eisai R&D Management Co., Ltd. Percutaneously absorbable preparation
US20110056863A1 (en) * 2008-05-30 2011-03-10 Junichi Sekiya Adhesive preparation containing donepezil, and package of the same
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
WO2010042612A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
ES2734510T3 (en) 2008-10-08 2019-12-10 Agile Therapeutics Inc Transdermal administration
TWI541246B (en) 2008-12-08 2016-07-11 歐陸斯迪公司 Dihydroetorphine
CA2751884C (en) * 2009-01-14 2018-09-25 Corium International, Inc. Transdermal administration of tamsulosin
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc Transdermal delivery
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
DE102010026879A1 (en) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermal system, useful for indicating and preventing multiple sclerosis, immunomodulator including quinolines or isoxazoles, metabolite forming groups, skin protective layer, a reservoir and a carrier impermeable to active substance
DE102010026883A1 (en) 2010-03-11 2011-12-15 Amw Gmbh Transdermal system useful e.g. for indication of breast cancer with progesterone-receptor positive status, comprises e.g. aromatase inhibitor, active substance puller protection layer, active substance reservoir
EP2377540A1 (en) 2010-03-31 2011-10-19 Hexal AG Transdermal patch containing 17-deacetyl norgestimate
RU2445084C2 (en) * 2010-04-27 2012-03-20 Государственное образовательное учреждение высшего профессионального образования Смоленская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию Transdermal plaster
DE102011100619A1 (en) 2010-05-05 2012-01-05 Amw Gmbh Therapeutic system, useful to treat chronic pain, comprises active agent impermeable carrier, active agent reservoir containing e.g. opioid receptor agonist, optionally active agent-permeable membrane and active agent impermeable layer
DE102010026903A1 (en) 2010-07-12 2012-01-12 Amw Gmbh Transdermal therapeutic system with avocado oil or palm oil as adjuvant
WO2012095548A2 (en) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compounds for treating neurodegenerative disorders
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
FR2992325B1 (en) 2012-06-26 2015-05-22 Ab7 Innovation MULTIFUNCTIONAL POLYURETHANE MONOPOLYMERIC MULTIFUNCTION SEQUENCE MATRIX AND MANUFACTURING METHOD
EP2915098A4 (en) 2012-10-30 2016-07-06 Certirx Corp Product, image, or document authentication, verification, and item identification
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
WO2015007326A1 (en) 2013-07-18 2015-01-22 Institut D'investigació Biomèdica De Bellvitge (Idibell) Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases
KR101881791B1 (en) * 2013-10-07 2018-07-25 테이코쿠 팔마 유에스에이, 인코포레이티드 Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
TWI629066B (en) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
KR101948779B1 (en) * 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 Dexmedetomidine transdermal delivery devices and methods for using the same
EP3054931B1 (en) * 2013-10-07 2020-12-23 Teikoku Pharma USA, Inc. Transdermal delivery device for managing pain comprising dexmedetomidine transdermal compositions
JP6188933B2 (en) 2013-10-07 2017-08-30 テイコク ファーマ ユーエスエー インコーポレーテッド Methods and compositions for transdermal delivery of non-sedating amounts of dexmedetomidine
EP2930238A1 (en) 2014-04-09 2015-10-14 Fundacio Centre de Regulacio Genomica Compositions for treating cancer
EP2949324A1 (en) 2014-05-27 2015-12-02 Consorci Institut Catala de Ciencies Cardiovasculars Prevention and/or treatment of ischemia/reperfusion injury
EP2957634A1 (en) 2014-06-20 2015-12-23 Consejo Superior De Investigaciones Científicas Compounds for prevention and/or treatment of fibrotic diseases
EP2977463A1 (en) 2014-07-25 2016-01-27 Centro de Investigación Biomédica en Red (CIBER) Methods and agents related to lung diseases
EP2987503A1 (en) 2014-08-22 2016-02-24 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and reagents for prevention and/or treatment of infection
EP2997977A1 (en) 2014-09-19 2016-03-23 Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3067369A1 (en) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the treatment of anti-angiogenic resistant cancer
EP3085366A1 (en) 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20180125860A1 (en) 2015-05-18 2018-05-10 Agile Therapeutics, Inc. Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects
KR102650751B1 (en) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 Implant placement and removal systems
EP3356384B1 (en) 2015-09-29 2023-11-29 Paris Sciences et Lettres Polypeptides comprising vinculin binding sites for the treatment of proliferation and/or adhesion related diseases
CN105416940A (en) * 2015-11-30 2016-03-23 芜湖成德龙过滤设备有限公司 Goods shelf convenient to clean
EP3219326A1 (en) 2016-03-14 2017-09-20 Institut Catalá De Ciencies Cardiovasculars (ICCC) Prevention and/or treatment of ischemia or ischemia/reperfusion injury
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3556359A4 (en) 2016-12-19 2020-08-05 Nutritape, S.L. Energising patch for sportspeople
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
WO2018162581A1 (en) 2017-03-07 2018-09-13 OP2 Drugs Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
EP3385276A1 (en) 2017-04-03 2018-10-10 Targedys Proteins derived from clpb and uses thereof
ES2932076T3 (en) 2017-10-27 2023-01-11 Association Pour La Rech A Ligbmc Ari Nonsteroidal Selective Glucocorticoid Receptor Agonist Modulators (SEGRAMs) and Uses Thereof
EP3569228A1 (en) 2018-05-17 2019-11-20 Association pour la recherche à l'IGBMC (ARI) Non-steroidal selective glucocorticoid receptor agonistic modulators (segrams) and uses thereof
EP3539975A1 (en) 2018-03-15 2019-09-18 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Micropeptides and uses thereof
US20220071330A1 (en) * 2018-08-07 2022-03-10 Erin Marie Tedesco Hair Extension Device and Method
IL281161B2 (en) 2018-09-06 2024-01-01 OP2 Drugs Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE655916C (en) * 1934-03-04 1938-01-25 Mitteldeutsche Stahlwerke Akt Thrust bearings for lock gates
ATE95430T1 (en) * 1984-12-22 1993-10-15 Sanol Arznei Schwarz Gmbh ACTIVE PATCHES.
CA1272445A (en) * 1985-02-25 1990-08-07 Yie W. Chien Transdermal pharmaceutical absorption dosage unit and process of pharmaceutical administration
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US5296230A (en) * 1985-02-25 1994-03-22 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4883669A (en) * 1985-02-25 1989-11-28 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
CA1288698C (en) * 1985-08-30 1991-09-10 Yie W. Chien Transdermal anti-anginal pharmaceutical dosage
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
JPH0720866B2 (en) * 1987-05-15 1995-03-08 三生製薬株式会社 Transdermal preparation containing eperisone or tolperisone or their salts
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US4898920A (en) * 1987-10-15 1990-02-06 Dow Corning Corporation Adhesive compositions, controlled release compositions and transdermal delivery device
US5656286A (en) † 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5788983A (en) * 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
US5232707A (en) * 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
US5252334A (en) † 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
DE3933460A1 (en) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts OSTROGEN-ACTIVE PLASTER
US5508038A (en) * 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
EP0555360A1 (en) * 1990-10-29 1993-08-18 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
DE4210711A1 (en) † 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De TRANSDERMAL THERAPEUTIC SYSTEMS WITH CRYSTALIZATION INHIBITORS
JP2960832B2 (en) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト Estradiol administration system
DE4227989A1 (en) * 1992-08-21 1994-06-09 Schering Ag Agent for transdermal application containing 3-keto-desogestrel
AU7396294A (en) * 1993-06-25 1995-01-24 Alza Corporation Incorporating poly-n-vinyl amide in a transdermal system
DE4333595A1 (en) * 1993-10-01 1995-04-06 Labtec Gmbh Transdermal therapeutic system for applying drugs to the skin
US5741511A (en) * 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
WO1996040087A2 (en) * 1995-06-07 1996-12-19 Cygnus, Inc. Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid

Also Published As

Publication number Publication date
JPH11501323A (en) 1999-02-02
DE69625483T2 (en) 2003-10-30
EP0836506B1 (en) 2002-12-18
PL181582B1 (en) 2001-08-31
NO975586D0 (en) 1997-12-03
DE69625483T3 (en) 2012-05-10
PL323729A1 (en) 1998-04-14
US5972377A (en) 1999-10-26
PT836506E (en) 2003-04-30
CA2222133C (en) 2002-12-24
ES2190472T5 (en) 2012-03-09
IL122432A0 (en) 1998-06-15
EP0836506A1 (en) 1998-04-22
AU703593B2 (en) 1999-03-25
KR19990022722A (en) 1999-03-25
CN1188189C (en) 2005-02-09
CZ292151B6 (en) 2003-08-13
HU228434B1 (en) 2013-03-28
IL122432A (en) 2000-07-16
DE69625483D1 (en) 2003-01-30
CZ393297A3 (en) 1999-06-16
EP0836506B2 (en) 2011-12-21
US6071531A (en) 2000-06-06
NZ311304A (en) 1999-03-29
EP0836506A4 (en) 1999-05-26
AU6259796A (en) 1996-12-30
US5876746A (en) 1999-03-02
DK0836506T3 (en) 2003-04-07
ATE229828T1 (en) 2003-01-15
KR100301226B1 (en) 2002-07-06
HUP9802326A2 (en) 1999-02-01
JP2004043510A (en) 2004-02-12
DK0836506T4 (en) 2012-01-30
ES2190472T3 (en) 2003-08-01
CN1190351A (en) 1998-08-12
MX9709666A (en) 1998-10-31
NO975586L (en) 1998-01-27
RU2177311C2 (en) 2001-12-27
UA48973C2 (en) 2002-09-16
HUP9802326A3 (en) 1999-07-28
NO316308B1 (en) 2004-01-12
JP3534775B2 (en) 2004-06-07
WO1996040355A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
CA2222133A1 (en) Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
NZ516502A (en) Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG)
AU1683088A (en) Compositions and methods of effecting contraception and control of breast cancer
CA2256977A1 (en) Methods of extended use oral contraception
DE69710896D1 (en) Progestogen-anti-progestogen therapien
KR960700727A (en) HORMONE REPLACEMENT THERAPY
AU645382B2 (en) Low estrogen oral contraceptives
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
MXPA02004084A (en) Hormonal composition based on a progesterone and an oestrogen and use thereof.
RU2005128284A (en) EXTENDED MODES OF PERCUTANEOUS CONTRACEPTION
CA2056364A1 (en) Compositions and methods of effecting contraception
Apgar A novel method of treating secondary amenorrhea in athletes
TH27339A (en) New drug-acting hormone and its benefits in treating estrogen deficiency

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160606